A granular cell tumor is a slow-growing, usually benign soft tissue growth that originates from Schwann cells, the cells that wrap around and insulate your nerves. These tumors get their name from the distinctive grainy appearance of their cells under a microscope. They’re uncommon but not extremely rare, and they most often appear in the head, neck, and skin of adults between 30 and 50 years old.
Where Granular Cell Tumors Develop
These tumors can show up almost anywhere in the body because nerves run through virtually every tissue. The most common locations are the skin and the tissue just beneath it, followed by the tongue (specifically the front two-thirds), esophagus, bronchus, and breast. Less frequent sites include the larynx, colon, vulva, and abdominal wall.
The tongue is a particularly well-known location. When a granular cell tumor appears there, it typically looks like a small, firm, yellowish or pinkish bump that doesn’t hurt. Granular cell tumors of the breast account for roughly 5 to 15% of all granular cell tumors but make up less than 1% of all breast tumors, which is part of what makes them tricky to identify in that location.
Who Is Most Likely to Get One
Granular cell tumors occur more often in women than men, particularly women between 30 and 50. They’re also more prevalent among African Americans compared to Caucasians. While middle-aged adults are the most commonly affected group, these tumors can appear at any age.
What They Look and Feel Like
On the skin, a granular cell tumor typically appears as a small, firm, solitary nodule that’s either skin-colored or brownish-red. Most are smaller than 3 to 4 centimeters. The majority are painless, though some people notice itching, skin dimpling, or a slight retraction of the skin over the lump.
When these tumors develop inside the digestive tract, they’re usually discovered during an endoscopy for an unrelated reason. They look like a hard, greyish-white bump beneath the lining of the esophagus or intestine, with normal tissue covering them. Nothing about their appearance during endoscopy reliably distinguishes them from other types of polyps, so a biopsy is almost always needed.
Why Breast Tumors Get Misdiagnosed
Granular cell tumors in the breast deserve special mention because they frequently mimic breast cancer on imaging. On a mammogram, they appear as dense, irregular masses with spiky borders, which is exactly what a malignant breast tumor looks like. On ultrasound, they show up as irregularly shaped dark masses with blurry edges. These features often lead radiologists to assign a high suspicion score, sometimes resulting in unnecessary aggressive surgery before the true diagnosis is confirmed.
There are subtle differences, though. Granular cell tumors of the breast tend to have a more uniform internal texture compared to cancers, which are often heterogeneous with tiny calcifications. Granular cell tumors also lack the surrounding tissue swelling that typically accompanies breast cancer. Still, distinguishing the two reliably requires a tissue sample examined under a microscope. The tumor is thought to arise from Schwann cells of the nerves running above the collarbone, and its tendency to grow in an infiltrative pattern is what creates those irregular, cancer-like edges on imaging.
How They’re Diagnosed
Because granular cell tumors look unremarkable on physical examination and imaging, the diagnosis almost always comes down to a biopsy. Under a microscope, the tumor cells are packed with tiny granules (actually lysosomes, the cell’s recycling compartments), giving the tumor its name.
To confirm the diagnosis, pathologists use a panel of protein markers. Granular cell tumor cells consistently stain positive for S100 (a protein found in nerve-related cells) and CD68 (reflecting the heavy lysosome content). They also stain for two additional markers, protein gene product 9.5 and inhibin-alpha, which together help distinguish them from other soft tissue tumors. This staining pattern holds regardless of where in the body the tumor is found and supports the understanding that these growths come from nerve sheath cells.
Benign Versus Malignant
The vast majority of granular cell tumors are benign. Only about 1 to 2% are malignant. Features that raise concern for a malignant tumor include rapid growth, a size larger than 5 centimeters, ulceration of the overlying skin, and evidence on imaging that the tumor is invading surrounding structures. Under the microscope, pathologists look for specific warning signs like abnormal cell shapes, visible cell division, and areas of tissue death to distinguish aggressive tumors from harmless ones.
Malignant granular cell tumors behave very differently from their benign counterparts. In a review of 41 malignant cases, the recurrence rate after wide surgical removal was 59%, highlighting how much more aggressive these rare variants can be.
Treatment and Recurrence
Surgery is the standard treatment for granular cell tumors, whether benign or malignant. The goal is to remove the entire tumor with a margin of healthy tissue around it. For benign tumors removed with clear margins (meaning no tumor cells are found at the edges of the removed tissue), the recurrence rate is low, ranging from 2 to 8%. When margins are positive, meaning tumor cells extend to the edge of what was removed, recurrence jumps to over 20%.
This emphasis on clean margins has made a technique called Mohs surgery an appealing option in certain cases. Mohs surgery removes tissue in thin layers, with each layer examined under a microscope before the next is taken. Because granular cell tumor cells are easy to identify with standard staining, this approach can achieve complete removal while preserving as much surrounding healthy tissue as possible. It’s particularly useful for tumors in cosmetically sensitive areas or locations where tissue conservation matters.
For malignant granular cell tumors, wider excision is typically necessary, and evaluation for spread to other parts of the body is an important part of the workup. These tumors can metastasize to lymph nodes, lungs, and bone, making early identification of malignant features critical for planning treatment.